Deals this week: Blue Oak Pharmaceuticals, Mustang Bio, iVeena Delivery Systems

8th December 2017 (Last Updated December 8th, 2017 00:00)

US-based therapeutics developer for brain disorders Blue Oak Pharmaceuticals Inc has collaborated with pre-clinical contract research and drug discovery services provider PGI Drug Discovery LLC (formerly PsychoGenics Inc).

US-based therapeutics developer for brain disorders Blue Oak Pharmaceuticals Inc has collaborated with pre-clinical contract research and drug discovery services provider PGI Drug Discovery LLC (formerly PsychoGenics Inc).

PsychoGenics will provide access to its phenotypic discovery platforms such as SmartCube system and machine learning expertise for disvover of therapeutics for brain disorders from chemotypes in Blue Oak library.

The partnership will allow the two companies to discover treatments for brain disorders.

Mustang Bio Inc  has partnered with Beth Israel Deaconess Medical Center Inc to develop CRISPR/Cas9-enhanced  chimeric antigen receptor engineered T cell (CAR T) therapies for cancer treatment.

Headquartered in the US, Mustang is a biopharmaceutical company engaged in the development of immunotherapies based on CAR T technology.

Mustang Bio has concurrently signed a licensing agreement with Harvard University to develop CRISPR/Cas9-enhanced CAR T therapies for cancer treatment.

iVeena Delivery Systems Inc has reached an agreement to secure funds in a venture financing round by issuing equity securities.

Based in the US, iVeena Delivery Systems develops ocular drug products.

Arena Pharmaceuticals Inc has partnered with Everest Medicines to commercialise oral, selective prostacyclin receptors (SIP) ralinepag and etrasimod, which are used for the treatment of pulmonary arterial hypertension and multiple autoimmune diseases respectively.

"Arena Pharma will secure $12m as an upfront payment and $212m as development and commercial milestone payments."

Arena Pharma will secure $12m as an upfront payment and $212m as development and commercial milestone payments under the terms of the partnership.

The drugs will be marketed in mainland China, Taiwan, Hong Kong, Macau, and South Korea.

Dublin-based biopharmaceutical firm Shire Plc  has signed a research agreement with Rani Therapeutics LLC for conducting exclusive research on the use of the latter’s pill technology for the oral delivery of factor VIII therapy for haemophilia A patients.

The agreement gives Shire an option to negotiate a license for the development and commercialisation of the pill delivery technology, upon completion of feasibility studies. Shire has also made an equity investment in Rani Therapeutics.

Neon Therapeutics Inc has secured a further $36m from its existing and new investors in a series B venture funding round, increasing its total funding to $106m.

The firm plans to use the latest funding for ongoing clinical development of its neoantigen vaccine NEO-PV-01, which is in Phase 1b development stage.

Part of the funds will also be used for the ongoing pre-clinical development of neoantigen T cell program NEO-PTC-01.

UK-based developer of stem cell technologies and cell therapies Plasticell Ltd has partnered with research organisation Anthony Nolan.

The agreement enables the firms to advance the clinical development of haematopoietic stem cell product derived from Plasticell’s ex vivo cord blood (CB).

Allogeneic haematopoietic stem cell transplantation (HSCT) is a cell replacement therapy used for the treatment of haematological disorders.